Post-hoc analysis of CARE study comparing effect of Cenerimod 4mg vs. PBO Mos. 4-6: >10% improvement in alopecia w/Cenerimod Mos. 2-6: >10% improvement in mucosal ulcers w/ Cenerimod Early improvement in alopecia & ulcers w/Cenerimod Promising? #ACR25 @RheumNow Abs2440 https://t.co/mAqmIQashr

• https://x.com/RHEUMarampa/status/1983260232655536303/photo/1

What's new in sjogren's? Promising phase III data of telitacicept (dual BLyS + APRIL neutralization) Pt in both dosing groups with decrease in ESSDAI compared to PBO but best results at higher (160mg) dose Similar rates of adverse events @RheumNow #ACR25 Abst LB11 https://t.co/r9JaVKzedH

• https://x.com/Dr_Brian_MD/status/1983251046290870387/photo/1

@RheumNow Plus a heap more biosimilars have broken through in the US in the last year. It feels the biosimilar era is now here stateside, too. #ACR25 FDA Update @RheumNow https://t.co/9RiyhbKXU4

• https://x.com/drdavidliew/status/1983238835724247300/photo/1

@RheumNow Obinutuzumab for lupus nephritis was a very recent FDA addition two weeks ago, and we’ll play catch-up with the hematologists to get familiar with it, including its safety profile #ACR25 FDA Update @RheumNow https://t.co/h6bf4roGzB

• https://x.com/drdavidliew/status/1983238079105409478/photo/1
• https://x.com/drdavidliew/status/1983238079105409478/photo/1
• https://x.com/drdavidliew/status/1983238079105409478/photo/1

Perhaps it was my ignorance, but a FDA-approved therapy for fibromyalgia was not on my 2025 bingo card. We’re not exactly overwhelmed with proven options for FM, the unmet need is so great, so the more, the better. #ACR25 FDA session @RheumNow https://t.co/wwWijl3IyW

• https://x.com/drdavidliew/status/1983236387387388230/photo/1

IgG4 - Rare but Rx Several studies #ACR25 @ACRheum were presented Outcome measures Rx #steroids #CD19 mAb #Inebilizumab 👍+RCT reduction of flares BTKi #Rilzabrutinib #Zanubrutinib #JAKi +RCT of #tofacitinib +steroids vs pred @ACRheum @RheumNow #ACR25 1163 LB02 0239 1172 https://t.co/xC3wgaN9bk

• https://x.com/Janetbirdope/status/1983233945102659935/photo/1

Agrawal et al. Case study of tofacitinib + bDMARDs in refractory IA. 7 SpA, 2 RA, 1 JIA. Effective and safe. @RheumNow #ACR25 Abstr#2338 https://t.co/Y0B3W4csJX

• https://x.com/RichardPAConway/status/1983230783952466190/photo/1

#ACR25 Abstr#LB11 2025 belongs to Sjogren! In patients with ESSDAI=>5, a Phase 3 RCT of Telitacicept (BAFF/APRIL-i) in China met primary endpoint; change in ESSDAI vs PBO. ESSPRI improved too! Wow! That PBO response was a flat line! Will need Global study @RheumNow #ACRBest https://t.co/LXxpBZPCtF

• https://x.com/Yuz6Yusof/status/1983228550187528205/photo/1

Eder et al. Deucravacitinib in PsA from POETYK-PsA stuides. Male and female patients had similar response rates at week 16. ACR 20 57% vs 51%, ACR50 27% vs 27%, ACR70 12% vs 10%, MDA 24% vs 20%. @RheumNow #ACR25 Abstr#2356 https://t.co/bImzTA7uUC

• https://x.com/RichardPAConway/status/1983225499255185474/photo/1

#ACR25 Abstr#LB10 Promising 4-Year data of Deucravacitinib in blinded phase 2 RCT +LTE study showed efficacy inc. LLDAS and CLASI-50 response were maintained/improved over time in #SLE No concerning safety signal. Looking forward to Phase 3 results next year @RheumNow https://t.co/fZv82zJ6Q4

• https://x.com/Yuz6Yusof/status/1983220916264771657/photo/1

#ACR25 How hard will you go & at what cost? A study in China using CD20/BCMA Bispecific autologous CAR-T showed profound depletion, normalisation of abs and good response in #SLE (10/11 had LN). But 2 had G3 infections & cytopenia. Presenters said some had IVIG @RheumNow #ACRBest https://t.co/TF0wpib5rr

• https://x.com/Yuz6Yusof/status/1983218032924119234/photo/1
• https://x.com/Yuz6Yusof/status/1983218032924119234/photo/1

#ACR25 Abstr#LB02 Is there a role for JAK-i for the treatment of IgG4-RD? Opel label RCT in China (N=58) showed NO relapse in Tofacitinib + GC taper vs GC Taper alone (54%). No serious infection. Interesting and a PBO-controlled is warranted @RheumNow https://t.co/dFvAmcGfCT

• https://x.com/Yuz6Yusof/status/1983213337606291939/photo/1